300439 Stock Overview
Provides clinical diagnostics reagents and instruments in China.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
Medicalsystem Biotechnology Co., Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥9.17 |
| 52 Week High | CN¥12.60 |
| 52 Week Low | CN¥7.28 |
| Beta | 0.32 |
| 11 Month Change | 3.03% |
| 3 Month Change | -14.46% |
| 1 Year Change | -20.19% |
| 33 Year Change | -56.60% |
| 5 Year Change | -35.38% |
| Change since IPO | -30.55% |
Recent News & Updates
Shareholder Returns
| 300439 | CN Biotechs | CN Market | |
|---|---|---|---|
| 7D | -0.3% | -1.4% | -1.6% |
| 1Y | -20.2% | -22.6% | -19.6% |
Return vs Industry: 300439 exceeded the CN Biotechs industry which returned -22% over the past year.
Return vs Market: 300439 matched the CN Market which returned -20.8% over the past year.
Price Volatility
| 300439 volatility | |
|---|---|
| 300439 Average Weekly Movement | 5.1% |
| Biotechs Industry Average Movement | 5.6% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in CN Market | 9.0% |
| 10% least volatile stocks in CN Market | 3.8% |
Stable Share Price: 300439 has not had significant price volatility in the past 3 months.
Volatility Over Time: 300439's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 2,164 | Ji Hua Zou | www.nbmksw.com |
Medicalsystem Biotechnology Co., Ltd. provides clinical diagnostics reagents and instruments in China. The company offers automated biochemistry analyzers and bio reagents; and automated chemiluminescence immunoassay analyzer; hematology analyzers and reagents; and glycated hemoglobin analyzer, blood lipid analyzer, POCT, microfluidic biochemical analyzer. The company also provides urine analyzers, urine sediment analyzers; PCR kit, antibody test kit, antigen and antibody test kit, and nucleic acid reagent for COVID-19.
Medicalsystem Biotechnology Co., Ltd Fundamentals Summary
| 300439 fundamental statistics | |
|---|---|
| Market cap | CN¥3.52b |
| Earnings (TTM) | CN¥264.24m |
| Revenue (TTM) | CN¥1.88b |
13.3x
P/E Ratio1.9x
P/S RatioIs 300439 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 300439 income statement (TTM) | |
|---|---|
| Revenue | CN¥1.88b |
| Cost of Revenue | CN¥1.03b |
| Gross Profit | CN¥844.29m |
| Other Expenses | CN¥580.06m |
| Earnings | CN¥264.24m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 29, 2024
| Earnings per share (EPS) | 0.69 |
| Gross Margin | 44.99% |
| Net Profit Margin | 14.08% |
| Debt/Equity Ratio | 1.7% |
How did 300439 perform over the long term?
See historical performance and comparison